利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.036 秒)

    Catalysts for radical polymerization
    2.
    发明授权
    Catalysts for radical polymerization 失效
    用于自由基聚合的催化剂

    公开(公告)号：US07737234B2

    公开(公告)日：2010-06-15

    申请号：US11997895

    申请日：2006-08-04

    申请人： Josef Michl ,  Kamesh Vyakaranam ,  Stefanie Koerbe

    发明人： Josef Michl ,  Kamesh Vyakaranam ,  Stefanie Koerbe

    IPC分类号： C08F4/52 ,  C08F30/06 ,  C07F5/02

    CPC分类号： C08F4/484 ,  C08F4/00 ,  C08F110/10 ,  C08F110/14 ,  C08F210/00

    摘要： Provided is a method for polymerizing a polymer precursor, comprising: contacting a polymer precursor with a lithium carborane catalyst and an initiator under polymerizing conditions. A reaction solvent may be used, but is not necessary. Also provided is a method of preparing lithium carborane polymers, comprising: contacting a lithium carborane polymer precursor having a terminal alkenyl or alkynyl group with an initiator and an optional reaction solvent under polymerizing conditions. Functionalized carborane anions are also provided.

    摘要翻译： 本发明提供聚合物前体的聚合方法，其包括：在聚合条件下使聚合物前体与锂碳硼烷催化剂和引发剂接触。 可以使用反应溶剂，但不是必需的。 还提供了一种制备锂碳硼烷聚合物的方法，其包括：在聚合条件下使具有末端烯基或炔基的碳硼烷锂聚合物前体与引发剂和任选的反应溶剂接触。 还提供功能化的碳硼烷阴离子。

    Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
    3.
    发明申请
    Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods 审中-公开
    胰腺癌相关抗原，抗体及其诊断和治疗方法

    公开(公告)号：US20060258841A1

    公开(公告)日：2006-11-16

    申请号：US10542239

    申请日：2004-01-16

    申请人： Josef Michl ,  Stefan Bradu ,  Raquib Hannan ,  Matthew Pincus

    发明人： Josef Michl ,  Stefan Bradu ,  Raquib Hannan ,  Matthew Pincus

    IPC分类号： C07K14/82 ,  C07K16/30

    CPC分类号： C07K16/303 ,  A61K47/6817 ,  A61K47/6859 ,  A61K51/1057 ,  A61K2039/505 ,  C07K14/47 ,  C07K2317/24 ,  C07K2317/734 ,  G01N33/57438 ,  G01N2333/705

    摘要： The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

    摘要翻译： 本发明涉及在大鼠和人胰腺癌细胞表面上发现的抗原，并且提供对该抗原以及分泌本发明抗体的杂交瘤具有高特异性和选择性的抗体。 还提供了胰腺癌诊断和治疗方法。 胰腺腺癌组织标志物，一种约43.5 kD的表皮膜蛋白，称为PaCa-Ag1，在正常胰腺中完全未表达，但在胰腺癌细胞中大量表达。 此外，使用受试抗体，存在可溶形式的PaCa-Ag1，其分子量约36至约38kD，其易于在胰腺癌患者的血清和其它体液中鉴定。

    Weakly nucleophilic anions
    4.
    发明授权
    Weakly nucleophilic anions 失效
    弱亲核阴离子

    公开(公告)号：US5731470A

    公开(公告)日：1998-03-24

    申请号：US628357

    申请日：1996-04-05

    申请人： Josef Michl ,  Benjamin T. King ,  Zbynek Janousek

    发明人： Josef Michl ,  Benjamin T. King ,  Zbynek Janousek

    IPC分类号： C07F5/02

    CPC分类号： C07F5/027

    摘要： Substituted borate and carborate anions having unusual properties of being exceptionally weakly nucleophilic and being soluble in non-polar solvents. One-electron oxidation of the anions yields the corresponding radicals. The compounds are useful, e.g., as electrolytes, catalysts, and electrochromic materials.

    摘要翻译： 具有非常弱的亲核性并且可溶于非极性溶剂的不寻常的特性的取代硼酸盐和碳化硼阴离子。 阴离子的一电子氧化产生相应的自由基。 这些化合物是有用的，例如电解质，催化剂和电致变色材料。

    PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
    5.
    发明申请
    PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS 审中-公开

    公开(公告)号：US20150320841A1

    公开(公告)日：2015-11-12

    申请号：US14809666

    申请日：2015-07-27

    申请人： Matthew Pincus ,  Josef Michl

    发明人： Matthew Pincus ,  Josef Michl

    IPC分类号： A61K38/46 ,  C12N15/86

    CPC分类号： A61K38/46 ,  A61K38/00 ,  A61K48/00 ,  C07K14/82 ,  C07K2319/10 ,  C12N15/86 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12Y306/05002

    摘要： The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.

    PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
    6.
    发明申请
    PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS 审中-公开

    公开(公告)号：US20130065953A1

    公开(公告)日：2013-03-14

    申请号：US13677876

    申请日：2012-11-15

    申请人： Matthew Pincus ,  Josef Michl

    发明人： Matthew Pincus ,  Josef Michl

    IPC分类号： A61K31/711 ,  A61P35/00 ,  C12N15/861

    CPC分类号： A61K38/46 ,  A61K38/00 ,  A61K48/00 ,  C07K14/82 ,  C07K2319/10 ,  C12N15/86 ,  C12N2710/10032 ,  C12N2710/10043 ,  C12Y306/05002

    摘要： The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.

    Method for preparation of carborane anions
    7.
    发明授权
    Method for preparation of carborane anions 失效
    碳硼烷阴离子的制备方法

    公开(公告)号：US07161040B2

    公开(公告)日：2007-01-09

    申请号：US10472329

    申请日：2002-04-01

    申请人： Andreas Franken ,  Benjamin T. King ,  Josef Michl

    发明人： Andreas Franken ,  Benjamin T. King ,  Josef Michl

    IPC分类号： C07C331/00 ,  C07C335/00 ,  C07C381/00

    CPC分类号： C07F5/027

    摘要： This invention relates to an improved method for making unsubstituted carborane anions and monosubstituted carborane anions of formula: (R—CBn—Hm′)− where n is an integer ranging from 5 to about 11 and m′ is an integer ranging from 5 to 16 where the relative values of n and m′ depend upon the exact structure of the carborane and the presence of a non-hydrogen substituent. m as used herein is an integer ranging from 5 to 16. When R is hydrogen the anion is unsubstituted. When R is a halogen, a phenyl, a substituted phenyl group, such as fluorophenyl group, or any other substituent, the carborane is substituted. The method is particularly useful for preparation of twelve-vertex carborane anions R—CB11H11−, where R is a defined above, and is specifically useful for preparation of the unsubstituted carborane CB11H12-??, where R is H.

    摘要翻译： 本发明涉及一种制备未取代的碳硼烷阴离子和具有下式的单取代的碳硼烷阴离子的改进方法：（R-CB N-H） - H SUP >其中n是5至约11的整数，m'是5至16的整数，其中n和m'的相对值取决于碳硼烷的精确结构和非氢取代基的存在。 m为5〜16的整数。当R为氢时，阴离子为未取代的。 当R是卤素时，苯基，取代的苯基，例如氟苯基或任何其它取代基，碳硼烷被取代。 该方法对于制备十二个顶点碳硼烷阴离子R-CB 11，其中R为上述定义，特别有用，以及 特别适用于制备未取代的碳硼烷CB 11 H 12 -12，其中R为H.

    Peptides selectively lethal to malignant and transformed mammalian cells
    10.
    发明授权
    Peptides selectively lethal to malignant and transformed mammalian cells 有权
    对恶性和转化的哺乳动物细胞选择性致死的肽

    公开(公告)号：US07883888B2

    公开(公告)日：2011-02-08

    申请号：US10549048

    申请日：2004-01-13

    申请人： Josef Michl ,  Jesko Koehnke ,  Matthew R. Pincus

    发明人： Josef Michl ,  Jesko Koehnke ,  Matthew R. Pincus

    IPC分类号： C12N15/00

    CPC分类号： C07K14/4746 ,  A61K38/00

    摘要： The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. The subject peptides are thus useful in treating neoplastic disease in an animal, preferably a human. Also provided are pharmaceutical compositions comprising the subject peptides admixed with a pharmaceutical acceptable carrier. Methods of treating neoplastic disease in a patient by administering a subject peptide fused at its carboxy terminal end to a membrane penetrating leader sequence are also provided. The present invention also provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence operably linked to a nucleotide sequence encoding a subject peptide. Methods of selectively killing cancer cells in a subject by administering a therapeutically effective amount of a subject AdV vector are also provided by the present invention.

    摘要翻译： 本发明提供对应于人p53蛋白的全部或部分氨基酸残基12-26的肽，当与透膜前导序列融合时，该肽对恶性或转化细胞致死。 因此，本发明的肽可用于治疗动物，优选人类的肿瘤性疾病。 还提供了包含与药学上可接受的载体混合的受试肽的药物组合物。 还提供了通过将其羧基末端融合的受试肽施用于穿透前导序列的方法来治疗患者的肿瘤疾病。 本发明还提供了复制无能力的腺病毒（Adv）载体，其包含可操作地连接到编码目标肽的核苷酸序列的启动子序列。 通过施用治疗有效量的受试者AdV载体选择性地杀死受试者的癌细胞的方法也由本发明提供。